Study guide

25.2 Retention, Destruction and Long-Term Access

ACRP CCRA Certified Clinical Research Associate Study Guide 2026 Exam

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Exam Format, Eligibility and Registration

1.1 Exam Format, Eligibility and Current References 1.2 Registration, Fees and Candidate Decisions

2 Chapter 2: CRA Responsibilities and Study Planning

2.1 The CRA Role, Data Integrity and Product Oversight 2.2 Official Blueprint and Study Strategy

3 Chapter 3: Protocols, Endpoints and Trial Design

3.1 Protocol Elements and Endpoint Hierarchy 3.2 Endpoint Interpretation and Eligibility Rationale 3.3 Eligibility Verification and Trial Designs

4 Chapter 4: Bias Control, Blinding and Product Information

4.1 Bias, Randomisation and Comparator Controls 4.2 Unblinding and Investigator Brochure Content 4.3 Reference Safety Information and IB Updates

5 Chapter 5: Estimands and Device Instructions

5.1 Estimands and Intercurrent Events 5.2 Device Instructions, Configuration and Training

6 Chapter 6: Ethical Foundations and Independent Oversight

6.1 Ethical Foundations and the 2024 Declaration of Helsinki 6.2 Vulnerability, Voluntariness and Compensation 6.3 IRB/IEC Composition and Independent Review

7 Chapter 7: Ethics Communication and Informed Consent

7.1 Ethics Reporting, Approval Status and Version Control 7.2 Informed Consent Information and Meaningful Choice 7.3 Consent Documentation, Special Circumstances and Updates

8 Chapter 8: Recruitment, Retention and Confidentiality

8.1 Ethical Eligibility, Recruitment and Retention 8.2 Privacy, Confidentiality and Appropriate Access

9 Chapter 9: Safety Definitions and Classification

9.1 Adverse Event Definitions and Actual Life-Threatening Risk 9.2 Seriousness, Severity and Medical Importance 9.3 Causality, Expectedness and Reference Safety Information

10 Chapter 10: Safety Detection, Reporting and Oversight

10.1 Detecting Events, AESIs and Collection Windows 10.2 Expedited Reporting and the Sponsor Awareness Clock 10.3 Immediate Site Reporting and Independent Safety Oversight

11 Chapter 11: Follow-Up, Adherence and Conflicts

11.1 Safety Communications, Reconciliation and Follow-Up 11.2 Adherence, Discontinuation and Participant Choice 11.3 Conflicts of Interest and Prorated Payments

12 Chapter 12: Development Stages and Product Management

12.1 Nonclinical Background and Human Pharmacology 12.2 Exploratory, Confirmatory and Therapeutic-Use Studies 12.3 Product Storage, Labelling and Excursion Response

13 Chapter 13: Accountability, Integrity and Regulatory Status

13.1 Product Accountability and Adherence Calculations 13.2 Potential Fraud, Misconduct and Evidence Preservation 13.3 Submissions, Authorisation Status and Trial Reporting

14 Chapter 14: Current GCP Principles and Delegation

14.1 The Eleven Current GCP Principles 14.2 Proportionality and Investigator Oversight 14.3 Delegation, Qualifications and Task Authority

15 Chapter 15: Oversight, Protocol Control and Amendments

15.1 Clinical Oversight and Immediate-Hazard Changes 15.2 Deviation Classification and Resolution

16 Chapter 16: Implementation and Trial Responsibilities

16.1 Amendment Implementation and Communication 16.2 Sponsor, Investigator and Service-Provider Roles

17 Chapter 17: Quality Planning, Root Causes and CAPA

17.1 Quality Planning and Risk Management 17.2 Root Cause Analysis and CAPA Design 17.3 CAPA Implementation and Effectiveness Verification

18 Chapter 18: Risk Assessment and Monitoring Methods

18.1 Risk Assessment and Centralised Surveillance 18.2 Monitoring Methods and Source Review

19 Chapter 19: Quality Metrics, Plans and Communication

19.1 KRIs, Acceptable Ranges and Trial-Level Quality 19.2 Monitoring Plans, Co-Monitoring and Communication

20 Chapter 20: Site Qualification and Readiness

20.1 Site Qualification and Investigator Capacity 20.2 Recruitment Feasibility and Evidence-Based Site Selection 20.3 Site Readiness and Activity-Specific Release

21 Chapter 21: Initiation, Equipment and Supplies

21.1 Initiation Training and Readiness Walkthroughs 21.2 Equipment, Maintenance and Study Supplies

22 Chapter 22: Samples, Diagnostics and Financial Feasibility

22.1 Specimens, Diagnostic Results and Rater Quality 22.2 Contracts, Budgets and Operational Feasibility

23 Chapter 23: Interim Monitoring and Reporting

23.1 Interim Visit Preparation and Consent Review 23.2 Monitoring Eligibility, Safety and Products 23.3 Investigator Debrief and Monitoring Reports

24 Chapter 24: Essential Records, Audits and Findings

24.1 Essential Records and Site/Sponsor Reconciliation 24.2 Version History, Resolution Evidence and Noncompliance 24.3 Audits, Inspections and Closure Planning

25 Chapter 25: Close-Out, Retention and Destruction

25.1 Close-Out, Archiving and Continuing Obligations 25.2 Retention, Destruction and Long-Term Access

26 Chapter 26: Source Records and Good Documentation

26.1 Source Records and Foundational ALCOA Principles 26.2 Good Documentation, Completeness and Corrections 26.3 Source Access, Certified Copies and Context

27 Chapter 27: Electronic Systems, Metadata and Queries

27.1 EDC Design and Fit-for-Purpose Systems 27.2 Audit Trails, Electronic Outcomes and Device Choice 27.3 Queries, Coding and Supported Clinical Meaning

28 Chapter 28: Dataset Finalisation and Critical Data

28.1 Safety Reconciliation and Dataset Finalisation 28.2 Critical Data, Acquisition Tools and Interim Findings

25.2 Retention, Destruction and Long-Term Access

Key Takeaways Explain This Topic AI

Portal closure and staff turnover require planned retention continuity.

Permanent replacement copies need relevant content, context and structure preserved.

Destruction needs appropriate authorisation, confidentiality controls and documentation.

Last updated: October 2026

Retention, Destruction and Long-Term Access

A site may hold source in an EHR, administrative records in an electronic ISF and laboratory outputs through another system. A sponsor may hold trial-level records in several controlled repositories. Record locations and links need to remain understandable. Unnecessary duplicate copies can create version confusion, while a broken reference can make essential evidence unavailable.

Original records generally remain with the responsible party that generated them. Some records belong only with the investigator/institution because they contain confidential participant information; some concern sponsor activities; others are relevant to both. Determine what each party needs to retain rather than forcing every repository to mirror the others. Preserve confidentiality and blinding when sharing relevant records.

Paper and electronic preservation

Medium or arrangement Risk Appropriate planning question

Paper charts Fire, water, deterioration or misfiling Are storage, retrieval and protection suitable?

Thermal output Fading Is a durable, appropriately verified record retained?

Electronic system Expired access, obsolete format or lost metadata Can data and context remain readable and retrievable?

Vendor portal Contract ends How will required records transfer or remain accessible?

Off-site archive Custodian or location changes Who can authorise retrieval and maintain confidentiality?

When a certified copy permanently replaces an original essential record, it should preserve the same information, including relevant context, content and structure. A PDF export may omit attachments, electronic signatures, audit history or dynamic information. Assess what is necessary and verify the conversion or migration. A visible page count alone is weak proof of a complete record.

A portal-closure example

A sponsor notifies a site that its study portal will close next month. The portal contains safety communications the investigator needs to retain and relevant training records. The site should identify what must be preserved, establish the authorised export/retention method, verify completeness and readability, and document the location. Downloading a few screenshots at the last minute can lose context and leave no reliable retrieval index.

If the portal also contains material the site should not receive, use an appropriately scoped transfer rather than a full unrestricted export. Preserve necessary attribution, dates and version history. The sponsor and institution should agree responsibilities and resolve failures before access ends. A closed vendor account is not an explanation that makes missing essential records acceptable.

Custodian and organisation changes

Investigators retire, institutions merge and service providers change. Maintain a current responsible contact and update relevant parties when custody or record location changes. The retention obligation should survive staff turnover. A personal laptop or former employee's password is not a durable institutional archive.

If sponsorship changes, preserve ownership/transfer records and inform the relevant parties as required. Verify that source access, trial data and ongoing participant support are not interrupted. A new sponsor should be able to understand the history rather than receiving only the latest cleaned-up documents. The CRA can identify and track gaps while responsible sponsor/institutional functions manage the transfer.

Controlled destruction

Before disposal, establish that applicable periods, sponsor needs and relevant holds have ended. Obtain required authorisation, identify the records and method, protect confidential information and document the disposition. Sponsor release cannot override a longer applicable legal requirement. Storage cost, a closed trial account or an expired software subscription does not itself authorise deletion.

Data and metadata may have linked retention needs. Deleting an audit trail while retaining final values can destroy the ability to explain corrections. Destroying specimen material and destroying associated clinical records are separate decisions. Follow the protocol, consent, applicable requirements and authorised retention process for each.

Monitoring verification

At close-out, verify more than an address on a checklist. Ask how a record will be requested, who will approve access, how retrieval will work and how electronic readability will be maintained. Review documentation supporting any migration and outstanding issues. Record the custodian and escalation route so a later inspection can obtain reliable evidence.

A sound archive preserves an honest history, including deviations and unresolved limitations. Do not remove superseded versions, signed forms or inconvenient correspondence to reduce storage. Traceability and appropriate accessibility are the purpose of retention; a neat binder that no longer explains the trial does not meet that purpose.

Testing future retrieval

An archive plan should be practical for someone who did not work on the trial. Select a representative record and establish how an authorised reviewer would locate it, request access and interpret the relevant attachments and metadata. Verify that the responsible institution can support the process after staff or vendors change. A backup demonstrates a potential recovery copy; it does not by itself establish that the record can be read and reconstructed. Appropriate testing and documented resolution of retrieval problems provide stronger assurance than a storage address or an untested promise of continued access.

Official sources

Checked October 18, 2026: ICH E6(R3), Principles and Annex 1 .